Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bemnifosbuvir (AT-511) 是一种口服活性抑制剂,抑制 HCV 病毒复制,具有全基因型抗病毒活性。它有效抑制 SARS-CoV-2 (COVID-19)感染 (EC90=0.47 μM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 892 | 现货 | ||
5 mg | ¥ 1,990 | 现货 | ||
10 mg | ¥ 3,230 | 现货 | ||
25 mg | ¥ 5,720 | 现货 | ||
50 mg | ¥ 8,250 | 现货 | ||
100 mg | ¥ 10,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,550 | 现货 |
产品描述 | Bemnifosbuvir (AT-511) is a novel phosphoramidate prodrug of 2'-fluoro-2'-C-methylguanosine-5'-monophosphate that has potent in vitro activity against HCV. |
靶点活性 | SARS-CoV-2:0.47 μM (EC90), HCV:5-28 nM (EC50) |
体外活性 | AT-511 is a novel phosphoramidate prodrug of 2'-fluoro-2'-C-methylguanosine-5'-monophosphate that has potent in vitro activity against HCV[1].In the absence of cells, AT-511 was stable when incubated in culture medium at 37°C for up to 24 h. AT-9010 was the predominant intracellular metabolite measured in all hepatocyte species and Huh-7 cell incubations with 10 μM AT-511 and, except in mouse hepatocytes,far exceeded intracellular AT-511 concentrations,demonstrating that the active TP was efficiently formed from its phosphoramidate protide in liver cells. In hepatocyte incubations, the relative levels of AT-9010 formed, and its accumulation over 24 h expressed as area under the curve or AUC0-24h; from most to least abundant, were rat>human >mouse >dog/monkey. |
体内活性 | Treatment with moxifloxacin every 8?hr was accompanied by longer survival than in any other group.Tissue cultures 30?hr after bacterial challenge showed considerably less bacterial growth in the spleens and lungs of moxifloxacin-treated animals than in the other groups, but not in their livers[2]. |
别名 | AT-511 |
分子量 | 581.53 |
分子式 | C24H33FN7O7P |
CAS No. | 1998705-64-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 95 mg/mL (163.36 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7196 mL | 8.598 mL | 17.196 mL | 42.99 mL |
5 mM | 0.3439 mL | 1.7196 mL | 3.4392 mL | 8.598 mL | |
10 mM | 0.172 mL | 0.8598 mL | 1.7196 mL | 4.299 mL | |
20 mM | 0.086 mL | 0.4299 mL | 0.8598 mL | 2.1495 mL | |
50 mM | 0.0344 mL | 0.172 mL | 0.3439 mL | 0.8598 mL | |
100 mM | 0.0172 mL | 0.086 mL | 0.172 mL | 0.4299 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Bemnifosbuvir 1998705-64-8 Microbiology/Virology Others Proteases/Proteasome HCV Protease SARS-CoV guanosine pangenotypic Hepatitis C virus SARS coronavirus inhibit HCV Inhibitor antiviral AT511 AT 511 nucleotide AT-511 phosphoramidate inhibitor